



DEPARTMENT OF CORRECTIONS
Administration



Title:	USE OF NALOXONE NASAL SPRAY	DOC Policy: 10.3.3
Effective:	06/01/2019	Supersedes: N/A
Applicability:	All Functional Units	
Directives Cross-Reference:	ORS 689.681 to .684 OAR 333-055-0110; OAR 333-055-0115 OAR 855-019-0450 to -460	
Attachments:	None	

I. PURPOSE

The purpose of this policy is to establish guidelines governing training, distribution, storage, maintenance and deployment of naloxone nasal spray by DOC employees.

II. DEFINITION

Naloxone nasal spray is an opioid antagonist that prevents opioid molecules from connecting with receptors in the brain. Naloxone nasal spray can be used to counteract an opioid overdose and keep an individual alive until EMS can arrive.

III. POLICY

A. Training

1. All employees will receive training at least biennially in the proper use of naloxone nasal spray, to include opioid overdose prevention, recognition, response, and the administration of naloxone.
2. Training will be conducted in accordance with Oregon Health Authority guidelines and Oregon Administrative Rules.

B. Distribution and Storage

1. All doses of naloxone nasal spray shall be supplied by DOC Health Services.
2. Naloxone nasal spray doses may be made available in the following locations as determined by the DOC Health Services Administrator:
 - a. AED machines;
 - b. Mailrooms;
 - c. Institution response teams; or

- d. State vehicles used to transport offenders.
3. DOC Parole and Probation Officers and other designated employees may be provided doses to be carried on their person.
4. Doses other than those covered in this section shall be stored in a DOC pharmacy only.

C. Maintenance and Replacement

1. The Functional Unit Manager or designee shall identify staff responsible for routinely inspecting naloxone nasal spray doses located in designated areas, but not carried on person.
2. Employees designated to carry naloxone nasal spray on their person shall be responsible for routinely inspecting assigned doses.
3. Doses found during inspection to be damaged, expired, or otherwise unserviceable shall be removed from circulation and discarded by the person responsible for inspection of the doses. This person will also notify the Functional Unit Manager or designee, in writing, of the removal reason.
4. Requests for replacement of damaged, expired, otherwise unserviceable, and deployed doses shall be made by the Functional Unit Manager or designee within 24 hours of removal from circulation.
5. Doses not damaged or determined to be unserviceable, shall be removed from circulation approximately 3 months prior to expiration and processed according to the direction of the Chief Pharmacy Officer. Replacements for soon to be expiring doses may be requested and received prior to removing expiring doses from circulation.

D. Naloxone Deployment

1. Employees at the scene of a potential opioid overdose should conduct an assessment of the individual in accordance with training received.
2. If it is determined that the individual has likely overdosed on an opioid, the employee should request emergency medical services as soon as practicable, notifying them of the potential state of overdose.
3. At the employee's discretion, naloxone may be administered in accordance with training received.

E. Documentation

1. Any employee who deploys naloxone nasal spray as a result of a potential overdose will complete a report documenting the circumstances. At a minimum, the following shall be included in the report:

- a. Date and time of the event;
- b. The circumstances that led the employee to believe an overdose had occurred;
- c. The number of naloxone doses administered;
- d. Any aftercare given;
- e. Whether the individual refused further medical treatment;
- f. The names of the medics present;
- g. The names of the employees present; and
- h. The name of the patient.

IV. IMPLEMENTATION

This policy will be adopted immediately without further modification.

Certified: _signature on file_____

Michelle Mooney, Rules Coordinator

Approved: _signature on file_____

Heidi Steward, Deputy Director